Zhejiang Wenda Pharmaceutical Technology Co., Ltd. (Wenda Pharma)

New Capabilities

Developer of NHWD-870; reported Phase II results at ESMO 2026

NUT carcinoma is rare, aggressive and has no approved targeted therapy. In a 40-patient Phase II trial reported at the European Society for Medical Oncology meeting in October 2026, Wenda Pharma's oral drug NHWD-870 shrank tumors in 30% of patients. Among 20 patients whose tumors started in the chest, 45% responded.

Updated Oct 29